GlassScriptPhysician profile
Jose C Lopez
NPI 1669515730
$8,480.99
in general payments reported to CMS, 2019-2025
29 companies · $282 in 2025
The $282 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $650 · 2020: $581 · 2021: $851 · 2022: $924 · 2023: $4,176 · 2024: $1,017 · 2025: $282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,353 · Food and Beverage: $2,122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,353.12 |
| Food and Beverage | $2,121.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $3,762.68 | 2023 | |
| Supernus Pharmaceuticals, INC. | $824.33 | 2023-2025 | Qelbree, Qelbree |
| Sunovion Pharmaceuticals INC. | $525.08 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $507.82 | 2019-2024 | Austedo Xr, Austedo |
| Takeda Pharmaceuticals U.S.A., INC. | $343.48 | 2020-2022 | |
| Abbvie INC. | $336.66 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $298.12 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $297.10 | 2020-2024 | Abilify Asimtufii, Rexulti |
| Alkermes, INC. | $197.70 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $168.54 | 2019-2024 | Invega Sustenna |
| Axsome Therapeutics, INC. | $157.77 | 2022-2025 | Auvelity |
| Allergan, INC. | $155.01 | 2020 | |
| Almatica Pharma LLC | $134.39 | 2022-2023 | Loreev Xr, Sertraline Hcl, Citalopram |
| Vanda Pharmaceuticals INC. | $128.72 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $124.31 | 2024-2025 | Cobenfy |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $115.20 | 2025 | Airsupra |
| Abbott Laboratories | $96.08 | 2024 | Aveir, Freestyle Libre 3 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $89.49 | 2021-2022 | |
| Eisai INC. | $54.70 | 2020 | |
| Lundbeck LLC | $42.36 | 2024 | Rexulti |
| Indivior INC. | $35.34 | 2019 | |
| Adlon Therapeutics L.P. | $31.23 | 2020 | |
| Tempus Ai, INC | $28.71 | 2024 | |
| Ironshore Pharmaceuticals INC. | $15.19 | 2024 | |
| Shire North American Group INC | $10.98 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.